Get started
Author

José Carlos Benítez

Observed names: J. Benítez, J.C. Benitez, J.C. Benítez, Jose Benitez-Montanez, Jose C. Benitez, Jose Carlos Benitez, Jose Carlos Benitez-Montanez, Jose Carlos Benítez, Jose-Carlos Benítez, José C. Benítez, José Carlos Benitez, José Carlos Benitez-Montañez, José-Carlos Benítez, José-Carlos Benítez-Montañez
Observed institutions: Université Paris-Saclay, Institut Gustave Roussy, University Hospital Mútua de Terrassa, Hospital Clínic de Barcelona, Mútua Terrassa, Andalusian Centre for Nanomedicine and Biotechnology, Hospital Clínico Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga, Fondation Gustave Roussy, Universidad Nacional Autónoma de México, Facultad de Estudios Superiores Iztacala, Universitat de Barcelona, Universidad de Málaga, Universidad Nacional Autónoma de México
ORCID: 0000-0002-8776-9132
Observed ORCID: 0000-0002-8776-9132
OpenAlex ID: A5056949923
Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression
2019 · Mihaela Aldea, Lizza Hendriks, et al. · Journal of Thoracic Oncology · 87
PDF
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy
2021 · A. Cortellini, B. Ricciuti, et al. · Annals of Oncology · 67
PDF
Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
2023 · Adrien Rousseau, Marco Tagliamento, et al. · European Journal of Cancer · 59
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
2020 · Andrea De Giglio, Laura Mezquita, et al. · Cancers · 57
PDF
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
2022 · Mariona Riudavets, Edouard Auclin, et al. · European Journal of Cancer · 56
Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non–Small-Cell Lung Cancer
2019 · Jordi Remon, Ludovic Lacroix, et al. · JCO Precision Oncology · 54
Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy
2020 · Jose Carlos Benitez, Jordi Remon, et al. · Clinical Cancer Research · 53
Clinical Relevance of an Amplicon-Based Liquid Biopsy for DetectingALKandROS1Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer
2020 · Laura Mezquita, Aurélie Swalduz, et al. · JCO Precision Oncology · 52
The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors
2020 · Jose C. Benitez, Gonzalo Recondo, et al. · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · 45
miR-21, miR-99b and miR-375 combination as predictive response signature for preoperative chemoradiotherapy in rectal cancer
2018 · Marc Campayo, Alfons Navarro, et al. · PLoS ONE · 40
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer
2023 · Edouard Auclin, Jose Benitez-Montanez, et al. · Lung Cancer · 29
The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients
2020 · Mihaela Aldea, Jose Carlos Benitez, et al. · Translational Lung Cancer Research · 29
PDF
Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer
2024 · Juan Zafra, Juan Luis Onieva, et al. · International Journal of Molecular Sciences · 20
PDF
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study
2021 · Nicolas Epaillard, Jose Carlos Benitez, et al. · Lung Cancer · 20
Consecutive Low Doses of Cyclosporine A Induce Pro-Inflammatory Cytokines and Accelerate Allograft Skin Rejection
2011 · Roberto López-Flores, Rafael Bojalil, et al. · Molecules · 18
PDF
Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial.
2024 · Joachim Aerts, Luis G. Paz-Ares, et al. · Journal of Clinical Oncology · 16
Micronodular thymic carcinoma with lymphoid hyperplasia: relevance of immunohistochemistry with a small panel of antibodies for diagnosis—a RYTHMIC study
2021 · Vincent Thomas de Montpreville, Audrey Mansuet-Lupo, et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 15
Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates
2024 · Filippo G. Dall’Olio, Wael Zrafi, et al. · Clinical Cancer Research · 13
Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study
2024 · Nuria Ribelles, Javier Pascual, et al. · JCO Global Oncology · 12
PDF
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group
2025 · Mariana Brandão, Elena Prisciandaro, et al. · Lung Cancer · 11
Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade
2023 · Javier Oliver, Juan Luis Onieva, et al. · Cancers · 9
PDF
Narrative review of immunotherapy in thymic malignancies
2021 · Jose Carlos Benitez, Benjamin Besse · Translational Lung Cancer Research · 9
PDF
Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal Cancer
2021 · Jose Carlos Benitez, Marc Campayo, et al. · Journal of Personalized Medicine · 8
PDF
An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update
2021 · Luigi Cerbone, Jose Carlos Benitez, et al. · Expert Opinion on Pharmacotherapy · 8
P1.28-09 Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel
2023 · M. Brandao, E. Prisciandaro, et al. · Journal of Thoracic Oncology · 7
PDF
Works count: 87
Citation count: 884
H-index: 16
I10-index: 20
Year
Topic
Type